CJC-1295 + Ipamorelin
Research-Grade GH Secretagogue Combination
Tagline: Synergistic GH Release Research
Product Description
CJC-1295 + Ipamorelin is a research combination pairing CJC-1295 (a GHRH analogue) with Ipamorelin (a selective ghrelin receptor agonist) to produce a synergistic stimulation of growth hormone (GH) secretion.
Researchers use this combination to study pulsatile GH release, IGF-1 production, body composition, recovery, and regenerative physiology in preclinical and in vitro models. This combination is especially valuable for exploring both hypothalamic and pituitary contributions to GH regulation.
For Laboratory and Scientific Research Use Only. Not for Human Consumption.
Why Researchers Choose CJC-1295 + Ipamorelin
-
Dual-Pathway Stimulation: Targets both GHRH and ghrelin receptor pathways for amplified GH release.
-
Pulsatile GH Secretion: Mimics natural GH pulse patterns, ideal for endocrinology research.
-
Synergy with IGF-1 Studies: Increases hepatic IGF-1 production for metabolic research.
-
Reduced Side Effects Profile: Ipamorelin is highly selective, with minimal prolactin/cortisol impact.
-
Batch Verified: Co-formulated and purity-confirmed for consistent dosing.
Important Note
For laboratory and scientific research only. Not for human consumption, veterinary use, or diagnostic purposes.




